Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10483381" target="_blank" >RIV/00064165:_____/24:10483381 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10483381
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=KD5vhZ.nPx" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=KD5vhZ.nPx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/14796694.2024.2372241" target="_blank" >10.1080/14796694.2024.2372241</a>
Alternative languages
Result language
angličtina
Original language name
Maintenance with mirvetuximab soravtansine plus bevacizumab vs bevacizumab in FRα-high platinum-sensitive ovarian cancer
Original language description
At first recurrence, platinum-sensitive ovarian cancer (PSOC) is frequently treated with platinum-based chemotherapy doublets plus bevacizumab, then single-agent bevacizumab. Most patients' disease progresses within a year after chemotherapy, emphasizing the need for novel strategies. Mirvetuximab soravtansine-gynx (MIRV), an antibody-drug conjugate, comprises a folate receptor alpha (FR alpha)-binding antibody and tubulin-targeting payload (maytansinoid DM4). In FR alpha-high PSOC, MIRV plus bevacizumab previously showed promising efficacy (objective response rate, 69% [95% CI: 41-89]; median progression-free survival, 13.3 months [95% CI: 8.3-18.3]; median duration of response, 12.9 months [95% CI: 6.5-15.7]) and safety. The Phase III randomized GLORIOSA trial will evaluate MIRV plus bevacizumab vs. bevacizumab alone as maintenance therapy in patients with FR alpha-high PSOC who did not have disease progression following second-line platinum-based doublet chemotherapy plus bevacizumab.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30214 - Obstetrics and gynaecology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Future Oncology
ISSN
1479-6694
e-ISSN
1744-8301
Volume of the periodical
20
Issue of the periodical within the volume
32
Country of publishing house
GB - UNITED KINGDOM
Number of pages
14
Pages from-to
2423-2436
UT code for WoS article
001283902300001
EID of the result in the Scopus database
2-s2.0-85200045710